Profiling metabolic changes in breast cancer with targeted proteomics by Stephan Bernhardt et al.
POSTER PRESENTATION Open Access
Profiling metabolic changes in breast cancer with
targeted proteomics
Stephan Bernhardt1*, Devina Mitra1, Zita Soons2, Rainer König3, Martina Vetter4, Christoph Thomssen4,
Eva Kantelhardt4, Stefan Wiemann1, Ulrike Korf1
From Metabolism, Diet and Disease 2014: Cancer and metabolism
Washington DC, USA. 28-30 May 2014
Background
Breast cancer is one of the most common causes of death
from cancer among women. Significant but yet insufficient
progress has been achieved due to the introduction of
targeted therapeutics [1]. Nevertheless, advancing persona-
lized medicine requires a detailed and comprehensive
molecular characterization, particularly at the protein
level. This project aims to advance the understanding
of crosstalk between cancer-relevant signaling and
metabolism.
Materials and methods
Based on a constructed flux distribution model, targets
where chosen to be analyzed in breast cancer cell lines
and tumor samples. The RPPA (reverse phase protein
microarray) technology a micro-scaled dot-blot approach
is used. RPPA allows to quantify protein expression and
activation states in a large panel of samples. In addition,
RPPA has a remarkable high sensitivity and is able to
analyze many proteins in a single experiment. Therefore
this method presents a powerful approach for targeted
hypothesis-based proteome research [2].
Results
As a first step, based on publically available transcript
data a model describing the deregulation especially of
glutamine and nitrogen metabolism in breast cancer was
developed [3]. Key features of our model are currently
evaluated by RPPA in cell lines representing the different
breast cancer subtypes. Metabolic enzymes confirmed on
the cell line level as de-regulated will be evaluated in
tumor samples and tested as putative drug targets in in
vitro models.
Conclusion
Based on the bioinformatic model and proteomic valida-
tion our aim is to introduce options for new co-treatment
concepts that target key metabolic enzymes to harm tumor
cells and disable their malignant anabolic processes, as well
as energy consumption. The resulting data will provide a
basis to calculate new models explaining the metabolic
shift in breast cancer cells and to identify signaling
molecules that contribute to malignant transformation.
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